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INTRODUCTION
Duchenne muscular dystrophy (DMD)
is a deadly genetic disease characterized
mainly by progressive weakness of the
skeletal musculature. Loss of ambulation
due to skeletal muscle degeneration is
the main recognizable phenotypical fea-
ture of patients with DMD. However,
more life-threatening complications de-
velop as the disease progresses, with
eventual cause of death in nearly all pa-
tients as a result of diaphragm and/or
cardiac muscle  failure (1).
Treatment options for DMD patients
are limited with virtually none currently
effective for ameliorating contractile
 dysfunction, including that of the dia -
phragm. However, we demonstrated re-
cently that NF-κB inhibition improved
contractility of diaphragm muscle in mdx
mice, a widely used mouse model of
DMD (2). Those data warranted further
investigation into the possibility of thera-
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peutically targeting the NF-κB signaling
pathway as a means of treating dys-
trophic pathology. Chronic activation of
the NF-κB signaling pathway has been
described in DMD patients (2,3) and this
activity occurs very early in the timescale
of the pathology (4). NF-κB was further
demonstrated to promote disease pro-
gression in mdx mice (2,5,6). Although
NF-κB inhibition has yet to be tested in
DMD patients (7), the current standard
care of using glucocorticoids exert their
beneficial effects partially through the
 inhibition of NF-κB (8,9). Thus, NF-κB
therapy may be considered beneficial for
the treatment of DMD.
Classical inflammatory NF-κB signaling
occurs in response to stimuli such as
TNFα and is mediated through the up-
stream IκB kinase (IKK) complex (10).
IKK consists of two catalytic kinase sub-
units, IKKα and IKKβ, and a regulatory
subunit named IKKγ (or NEMO for
NF-κB Essential Modulator) (11). Inactive
NF-κB heterodimers composed of p65-p50
are maintained predominately in the cyto-
plasm by inhibitor IκB proteins. Phospho-
rylation of IκB by IKK signals ubiquitina-
tion and subsequent degradation of IκB
by the 26S proteasome, thus allowing p65-
p50 to localize to the nucleus, bind DNA,
and cooperate with basal transcription
factors and coactivators to induce tran-
scription of target genes (12).
An IKK complex containing NEMO is
critical for inflammatory signaling
through the classical NF-κB pathway
(13,14). When the association between
IKKα and IKKβ and NEMO is disrupted,
inflammatory signaling through IKK is
impeded. In our previous investigation,
we took advantage of this critical associ-
ation to inhibit classical NF-κB signaling.
We demonstrated that a cell-permeable
11 amino acid peptide that binds to the
C-terminal region within IKKα and IKKβ
and prevents association with NEMO,
called the NEMO Binding Domain
(NBD) peptide, blunts the chronic NF-κB
signaling in mdx mice (2). This peptide
effectively ameliorated pathology in the
 muscles of mdx mice by reducing inflam-
mation and enhancing regeneration, and
improved functional deficits in the dia-
phragm significantly when compared
with administration with a mutant ver-
sion of NBD.
In addition to NBD, other anti-NF-κB
pharmacological and biological agents
(5,15–21) have been shown to be effica-
cious in rescuing mdx pathology to varying
degrees. However, unknown at this point
is whether any of these agents are suitable
for development into clinically useable
drugs. We reasoned that such a compound
would need to exhibit significant func-
tional improvement to the diaphragm
since this is the muscle in mdx mice that
most closely recapitulates the dystrophic
process in DMD patients (22). We are
mindful that the amount of improvement
needed in a rodent model to increase mus-
cle strength or quality of life in a DMD pa-
tient is difficult to predict because of in-
traspecies differences. Nevertheless, in an
effort to move toward our goal of deter-
mining whether NBD can be developed as
a therapeutic for the treatment of DMD,
we performed this study to assess doses
and formulations of NBD that are effica-
cious for improving diaphragm and limb
muscle function in the mdx mouse.
MATERIALS AND METHODS
Mice
Mice (mdx [C57BL/10 ScSn DMDmdx])
purchased from The Jackson Laboratory
(Bar Harbor, ME, USA) were housed and
bred in the animal facilities of The Ohio
State University College of Medicine,
under conventional conditions with con-
stant temperature and humidity and fed a
standard diet. Both male and female mdx
mice were used for these studies. Animal
experimentation was approved by The
Ohio State University Institutional Animal
Care and Use Committee.
Peptide Synthesis
The original NBD peptide (TALDW
SWLQTE), fused to an Antennapedia pro-
tein transduction domain (23), was gen-
erated by using an ABI 430A solid-phase
peptide synthesizer (Applied Biosystems,
Foster City, CA, USA) with standard
tBOC (tert-butyloxycarbonyl)-chemistry
(Yale University, New Haven, CT, USA).
The peptide was cleaved from the resin
and deprotected by using hydrofluoric
acid. Resulting crude materials were
 purified by HPLC on a Vydac (Vydac
Separations, Hesperia, CA, USA) C18
preparative column by using gradients of
acetonitrile in 0.10% trifluoroacetic acid
(TFA). Following lyophilization of the
purified fractions, the expected molecu-
lar weight of the peptide was confirmed
by using matrix-assisted laser desorption
ionization mass spectrometry. The result-
ant peptide was soluble in DMSO, the
same as used by our group previously (2).
GLP grade NBD peptide was pro-
duced by American Peptides (Sunnyvale,
CA, USA) by using similar procedures to
the original NBD peptide except with an
additional purification step in which gra-
dients of acetate rather than TFA were
used to elute peptide from the column.
This form is called GLP-NBD.
For conversion of NBD from an acetate
salt to TFA, peptide was dissolved in a
minimum amount of 1:1 acetonitrile/
water. For every 10 mg of peptide used,
18 μL of TFA was added and mixed. The
solution then was frozen by using a dry
ice and isopropanol mixture and subse-
quently lyophilized. The peptide was re-
suspended with an acetronitrile/water
mixture and TFA, and lyophilization
steps were repeated an additional two
times. This procedure maintained NBD
as a water-soluble peptide, which we
refer to as TFA-NBD.
Treatment Regimen
Mdx mice between 3.5 to 4 wks of age
were treated with peptides at a dose of
40 or 200 μg/mouse 3× weekly by IP in-
jections for a period of 4 wks. Although
exact delivery varied slightly, these doses
provided an average of 2 or 10 mg/kg,
respectively, over the course of the 4-wk
treatment period. Vehicle control mdx
mice were dosed in a similar manner ex-
cept, rather than peptide, only the vehi-
cle (10% DMSO/90% saline) was in-
jected. Aged matched wild-type (WT)
C57/BL10 mice were included as con-
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trols. For GLP synthesized peptides
(GLP-NBD and TFA-NBD), water was
used as the vehicle.
Diaphragm Force Measurements
After anesthetizing the mice (urethane,
200 mg in 0.7 mL i.p.), the thorax was
opened, and the diaphragm, attached to
part of the ribcage, was removed. 1.2- to
1.9-mm–wide sections (with a length
from rib to tendon) of diaphragm were
isolated in presence of BDM to minimize
cutting damage (24), and attached to a
force transducer (KG7, Scientific Instru-
ments, Heidelberg, Germany) and a mi-
crometer screw that allows for the adjust-
ment of muscle length. All contraction
experiments were done at 37° C. Al-
though this temperature deviates from
previously established guidelines, it bet-
ter reflects the physiological temperature
for in vivo diaphragm contraction, and
thus maximizes extrapolation of the data
obtained to the physiological in vivo situ-
ation. Moreover, this temperature is in-
line with our own previous studies
(2,25,26), and similar/ identical experi-
ments have been done by other laborato-
ries (27–29), indicating feasibility of body-
temperature experiments. The muscle
was then stretched to the length where
twitch contractions are optimal, and al-
lowed to rest for 10 min. Thereafter, they
were subjected to a protocol consisting of
a series of eight tetanic contractions occur-
ring at 2-min intervals, each with dura-
tion of 100 ms with paired-pulse trains of
stimuli at 20, 50, 80, 120, 150, 180, 200, and
250 Hz respectively. Force measurements
were normalized to cross-sectional area.
All assessments and data analysis were
done with the investigator blind to the
treatment of the mice. To further reduce
variability of muscle measurements that
are inherent to the preparation, time/ per-
sonnel permitting, two strips per mouse
were measured, and the data was aver-
aged per mouse for inclusion as a single
measurement point in the statistical anal-
ysis. Following removal of the  diaphragm
strips, the remainder of the diaphragm
muscle was prepared for histological and
biochemical analysis.
Whole Body Functional Measurements
Mice were subjected to an exercise
 regimen that included five successive
days of treadmill running at a speed of
25 meters/min at a 15% incline for 35
min. Functional measurements were then
obtained by performing rotarod strength/
endurance tests where the time of la-
tency to fall was recorded at 25 rpm for
180 seconds.
Assessment of Peptide Stability
Aliquots of NBD either were freshly
prepared or stored at different tempera-
tures for different times, and subsequently
analyzed by mass spectrometry. LC-
MS/MS was performed on an Ultimate
3000 system (Dionex, Sunnyvale, CA,
USA) coupled with an LTQ Orbitrap XL
high-resolution mass spectrometer
(Thermo Finnigan, San Jose, CA, USA).
Forty nanograms of the sample were in-
jected onto a reversed-phase C18 column
(Michrom Bioresources, Auburn, CA,
USA, Magic C18AQ, 200 μm × 150 mm, 
3 μm, 200 Å) at a flow rate of 2 μL/min.
Sample was eluted by using a linear gradi-
ent of mobile phase A (0.1% formic acid)
and mobile phase B (0.1% formic acid in
acetonitrile). The gradient increased from
2% B to 35% B in 28 min, then to 50% in 
5 min and 90% in 4 min. Heated capillary
temperature and electrospray voltage
were 175°C and 2.0 kV, respectively. The
mass spectrometer was operated in data-
 dependent MS/MS mode in which each
full MS scan is followed by five MS/MS
scans where the three most abundant pep-
tide ions were selected for CID by using a
normalized collision energy of 35%. Data
were then analyzed manually.
EMSA and Reporter Assays
EMSA and reporter analyses were per-
formed as described previously (30,31).
For EMSA, nuclear extracts were pre-
pared from either muscle tissues, or from
C2C12 myotubes that were left untreated
or treated for 30 min with TNFα. Treated
cells were incubated for 1 h prior to
TNFα treatment with vehicle (water) or
increasing concentrations of TFA-NBD.
Reporter assays were performed on
C2C12 myotubes containing an NF-κB
responsive luciferase reporter. Myotubes
were left untreated or preincubated for
1 h with either water or TFA-NBD. TNFα
then was added to activate NF-κB and
after 4 h, cells were harvested and pre-
pared for luciferase assays.
Histology
Serial frozen muscle sections (10 μm)
were cut from the proximal, midbelly,
and distal portions of the TA. For dia-
phragm, serial sections from muscle
strips not used for functional analysis
were cut in three separate places along
the muscle in an attempt to obtain analy-
sis representative of the entire muscle.
Sections from each portion of the mus-
cles were labeled for immunofluores-
cence. Primary antibodies were E-MyHC
(1:50; Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA,
USA), Collagen IV, (1:500; Millipore, Bil-
lerica, MA, USA), and F4/80 (1:200;
Serotec, Kidlington, UK). Alexa Fluor
488– and Alexa Fluor 568–conjugated
secondary antibodies (1:250; Molecular
Probes; Invitrogen, Carlsbad, CA, USA)
were used for indirect immunofluores-
cence, and DAPI was used for nuclear
detection. Staining was quantitated on an
Olympus BX51 microscope with Micro-
suite Five software (Olympus Soft Imag-
ing Solutions GmbH, Center Valley, PA,
USA). Three entire sections (one from
each portion of the muscle cut) were ana-
lyzed. Sections were quantitated by cal-
culating the percentage of a section posi-
tive for IgG, eMyHC or F4/80 staining in
proportion to the total area of the section
(positive area/total area × 100%).
Statistics
Contractile forces were analyzed by
using unpaired t tests and analysis of vari-
ance (ANOVA), followed by post hoc t tests
where applicable. A maximum of two mus-
cles per mouse were included in the study,
and these were averaged per mouse for sta-
tistical analyses. Histology was analyzed
by using an unpaired Student t test. A two-
tailed P value of < 0.05 was considered sig-
nificant. Data are given as mean ± SEM.
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RESULTS
We initiated our study by using the
same non-GLP version of the NBD pep-
tide that we and many other laboratories
have used to demonstrate NF-κB in-
volvement in a specific model of disease
(13,23,32–37). This peptide is formulated
in DMSO and was administered as a 10%
solution in saline. The final dose of the
compound was 200 μg per mouse,
which, at the weights of the animals that
we were using, converts approximately
to a dose of 10 mg/kg. We found that the
formulation of NBD as used in our stud-
ies, soluble in DMSO, exhibited consider-
able stability as assessed by mass spec-
trometry analysis. When compared with
freshly prepared peptide, NBD remained
stable after 1-day storage at room tem-
perature and 2 wks at 37° C (Figure 1A).
To determine how effective NBD was
in restoring whole body function, we ad-
ministered this peptide over a 4-wk pe-
riod to male and female mdx mice, and
rotarod strength/endurance tests subse-
quently were performed at 8 wks of age.
Results from a treadmill exercise regi-
men showed that after 4 d of exercise,
vehicle-treated (10% DMSO, 90% saline)
mdx mice had a 20% to 25% reduction in
whole body muscle strength/endurance,
while animals treated with NBD exhib-
ited a 16% (ANOVA, P < 0.05) improve-
ment over this level (Figure 1B). This
equated to a functional rescue of be-
tween 64% to 80% toward that of WT
mice (deficit between WT and vehicle-
treated mdx taken as 100% deficit). Simi-
lar results were obtained when perform-
ing an endurance test after 5 d of
treadmill running (data not shown), and
no differences between male and female
mice were observed in any of the
groups. Therefore, in the subsequent
studies, both genders were used for
analysis.
Next, specific diaphragm contractile
function was assessed. Vehicle-treated
WT (n = 16 from 10 mice) and vehicle-
treated mdx (n = 37 from 22 mice) mus-
cles were measured longitudinally to
mdx mice subjected to various treatment
regimens over the duration of the entire
project, always with the use of an identi-
cal protocol. The specific force generated
by 150 Hz tetani in WT mice was on av-
erage 167 mN/mm2. Owing to the
paired-pulse protocol used in our stud-
ies, at lower frequencies we already ob-
tained maximal tetanic force, an average
of 181 mN/mm2 in WT mice. These lev-
els of specific force are nearly identical
with similar studies performed at 37° C;
180 mN/mm2 by Rucker et al. (29),
172 mN/mm2 by Prezant et al. (28), and
190 mN/mm2 by Diaz et al. (27). In WT
mice that received our protocols, the iso-
metric single-pulse twitch-to-isometric
tetanus ratio was 3.6 ± 0.6, a value in-line
with all above-mentioned previous stud-
ies, and was not different in any of the
treatment groups. We found that at an
initial frequency of 20 Hz, WT dia-
phragm muscles generated 62% (P <
0.005) more force than muscles from mdx
vehicle-treated mice. At this same stimu-
Figure 1. NBD peptide is stable and improves mdx whole body function. (A) Mass spec-
trometry analysis of a NBD peptide depicts the strong stability of such a peptide after 1 d
at room temperature and 2 wks at 37° C. (B) Rotarod strength/endurance measurements
recorded from male and female WT or mdx mice treated with vehicle or NBD. Duration of
treatment was 4 wks starting at 4 wks of age. Rotarod latency time was statistically differ-
ent between NBD and vehicle mdx treated groups, but not between genders. *P < 0.05.
Figure 2. NBD treatment improves dia-
phragm contractility and is dose depen-
dent. Measurements of diaphragm
tetanic force were assessed at 37° C at
specific forces of 150 Hz. Values were av-
eraged from WT (n = 16 muscles/10 mice),
vehicle-treated mdx mice (Vehicle, n =
37 muscles/ 22 mice) and NBD (40 μg, n =
22 muscles/ 12 mice, and 200 μg, n = 25
 muscles/ 14 mice) treated mdx mice. Du-
ration of treatment was 4 wks starting at 
4 wks of age. The lower dose was much
less effective than a higher dose at improv-
ing  diaphragm contractile force. *P < 0.05.
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lation, NBD treatment (25 muscles from
14 mice) improved mdx diaphragm func-
tion by 43%, representing an average res-
cue toward WT of 78%. Significantly, this
difference in force by NBD was main-
tained at the tetanic frequency of 150 Hz
(Figure 2A).
We considered whether a similar effi-
cacy in mdx mice could be achieved by
using a lower dose of NBD. We reasoned
that obtaining a similar improvement
would be beneficial from a cost perspec-
tive as well as from a potential safety
profile. Therefore, treatments were re-
peated with the identical protocol except
that five times less peptide was used.
However, as results show (see
Figure 2A), administrating NBD at a
dose of 40 μg/mouse exhibited only a
marginal improvement in diaphragm
function (n = 22 muscles from 12 mice)
over that of mdx vehicle-treated mice
compared with WT or mdx mice treated
with the original higher dose. These re-
sults suggest that under the current ex-
perimental approach, NBD improvement
of mdx  muscle function requires a dose
above 40 μg/mouse.
In our efforts to develop NBD as a
compound suitable for the clinic, a ver-
sion of the peptide was synthesized
under GLP conditions. The amino acid
sequence including the Antennapedia
protein transduction domain was identi-
cal to the parent non-GLP compound.
However, the new version was soluble in
water, which we considered beneficial
for patient safety. Unfortunately, in sharp
contrast to the parent compound (NBD),
GLP-NBD showed only marginal and
statistically nonsignificant improvement
in diaphragm function of mdx mice (n =
15 muscles from nine mice, Figure 3).
This less than efficacious response was
maintained over the entire range of fre-
quency stimulations, leading us to con-
clude that the GLP-NBD peptide did not
provide a significant functional benefit to
dystrophin-deficient respiratory muscles.
Given this result, it was pertinent to
dissect the differential responses between
the NBD and GLP-NBD peptides. Be-
cause the sequences of these compounds
were identical, we reasoned that one ex-
planation for the discrepancy in our re-
sults could be due to the manner in
which each peptide was purified. Produc-
tion of NBD utilized TFA as a counterion
in the standard reverse phase HPLC pu-
rification phase, while GLP-NBD was
generated with an extra purification step
using acetate as a counterion. We thus
speculated that the counterion that re-
mained along with NBD during the
lyophilization step could account for the
solubility differences and thus potentially
also explain differences in the functional
outcome we observed. To test this possi-
bility, we changed the purification coun-
terion in GLP-NBD from acetate to TFA
in an attempt to mimic the initially pro-
duced version of NBD. This formulation
of the peptide was called TFA-NBD. Im-
portantly, TFA-NBD was still soluble in
water. However this advantage in solu-
bility was in exchange for a marginal loss
of peptide stability, as detected by mass
spectrometry (data not shown).
To test the efficacy of the TFA-NBD
peptide in vitro, C2C12 myotubes were
pretreated with peptide and subse-
quently stimulated with TNFα for
30 min, at which time cells were har-
vested and analyzed for NF-κB DNA
binding activity by an electrophoretic
mobility shift assay (EMSA). Results
showed that TFA-NBD, at two separate
doses, was effective at inhibiting NF-κB
DNA binding (Figure 4A). Similar results
were obtained when TFA-NBD was tested
for the ability to inhibit NF-κB transcrip-
tional activity by using an NF-κB respon-
sive reporter (Figure 4B). We next tested
the ability of TFA-NBD to attenuate NF-
κB activation in the muscles of mdx mice.
After 4 wks of treatment (starting at 4
wks of age), NF-κB DNA binding was
generally reduced in diaphragm muscles
of TFA-NBD treated versus vehicle
treated mdx mice (Figure 4C). These re-
sults support that TFA-NBD was indeed
inhibiting NF-κB activity in vivo. Most
importantly, when TFA-NBD was tested
for efficacy in mdx mice, a 37% (P < 0.05)
improvement in diaphragm function (n =
18 muscles from 11 mice) was achieved
compared with control (Figure 4D). This
represented a 63% rescue of the gener-
ated force produced by WT muscles, an
improvement that was maintained over
the entire range of tetanic frequencies
employed. These values of improvement
were within the statistical range recorded
for the original DMSO NBD peptide, in-
dicating that we were able to achieve di-
aphragm functional rescue successfully
with an NBD peptide formulation
viewed more favorable for clinical use.
In addition to rescuing functional
deficits in mdx mice, our previous results
demonstrated that the DMSO NBD ver-
sion of NBD was efficacious both in re-
ducing injury and inflammation and in
enhancing regeneration of mdx limb
muscles (2). To assess whether similar
benefits could be achieved with TFA-
NBD, we performed histological analyses
with skeletal muscles isolated from
treated mdx mice. Results showed that
TFA-NBD treatment was successful in re-
ducing myofiber damage in diaphragm
muscles by 79%, and to a lesser extent
(64%) in limb muscles, as measured by
IgG accumulation that reflects the level
Figure 3. GLP-NBD does not improve mdx
diaphragm function significantly. Compos-
ite representation of the force generated
from diaphragm muscles at 150 Hz tetanus
frequency from WT (n = 16 muscles/
10 mice), vehicle-treated mdx (n = 37
 muscles/22 mice), and mdx treated with
GLP-NBD (n = 15). Duration of treatment
was 4 wks starting at 4 wks of age. *P <
0.05 between indicated groups.
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of muscle damage due to necrosis (Fig-
ure 4E). Macrophage accumulation,
using F4/80 as a marker, also was re-
duced in diaphragm and limb muscle of
mice treated with TFA-NBD (Figure 4F)
by 56% and 72% respectively. Further-
more, eMyHC (embryonic myosin heavy
chain) expression was significantly in-
creased by 92% in diaphragm, and by
478% in limb muscles (Figure 4G), signi-
fying that TFA-NBD treatment also pro-
duces a robust regenerative response that
Figure 4. Conversion to TFA-NBD is effective in inhibiting NF-κB and improving diaphragm function and histopathology of mdx mice signifi-
cantly. (A) EMSA analysis from untreated or TNFα treated C2C12 myotubes exposed to vehicle (water), 50 μmol/L, or 100 μmol/L of TFA-
NBD. (B) C2C12 myotubes containing an NF-κB responsive luciferase reporter either were left untreated or were treated with TNFα after
being exposed to either water, 100 μmol/L TFA-NBD or 200 μmol/L TFA-NBD. (C) EMSA analysis from vehicle or TFA-NBD treated diaphragm
muscles. Duration of treatment was 4 wks starting at 4 wks of age. (D) Force measurements set at 150 Hz tetanus frequency were gener-
ated in diaphragm muscles from mdx mice treated with NBD converted to TFA (TFA-NBD, gray bar, n = 18 muscles/11 mice) compared
with levels obtained with vehicle (mdx, hatched, n = 37 muscles/22 mice) and WT mice (open, n = 16 muscles/10 mice). (E–G) Percent-
ages of total area within diaphragm and tibialis interior (TA) muscle sections positive for IgG (F), F4/80 (G) and eMyHC (H) between
 vehicle- and TFA-NBD-treated mice. *P < 0.05 among groups.
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is characteristic of NF-κB inhibition in
the presence of muscle injury. Together,
these data demonstrate that in addition
to providing similar functional rescue,
TFA-NBD is equally effective for alleviat-
ing inflammation and myofiber injury
and promoting muscle regeneration.
DISCUSSION
In this study we performed an analysis
to carefully evaluate the efficacy and fea-
sibility of pursuing NBD as a therapeutic
for DMD patients. Using a functionally
effective, but clinically unsuitable pep-
tide as a template, we were able to for-
mulate a NBD peptide successfully that
meets preclinical trial standards (GLP
grade) and maintains reasonable stability
dissolved in a nontoxic solution (water).
Most importantly, the final peptide for-
mulation retained the ability to rescue
functional and histological dystrophic
pathology in mice. These favorable find-
ings support continued efforts to pursue
NBD therapy as a treatment for DMD.
Given the devastating effects compro-
mised diaphragm and limb muscle func-
tion have on DMD patients, a therapy
capable of improving all skeletal mus-
cles is of paramount importance both for
extending life span and for maintaining
a good quality of life. Unfortunately,
many treatment strategies are being de-
veloped specifically to combat limb
muscle dysfunction while potentially
leaving diaphragm untreated. Our data
supports the use of NBD therapy for
treatment of both respiratory and limb
muscle pathology in DMD. To the best
of our knowledge, no other pharmaco-
logical therapy has shown the high de-
gree of diaphragm functional rescue that
we were able to achieve treating mdx
mice with NBD.
NF-κB is a vital signaling pathway rel-
evant at the cellular level for regulating
functions such as survival, apoptosis and
proliferation as well as for whole body
welfare, regulating critical genes involved
in immune responses (38). Consequently,
inhibiting all signaling through NF-κB
likely would result in a therapy where
the negative side effects outweigh the de-
sired efficacy of the treatment. A major
advantage of using the NBD peptide
therapeutically is that it does not interfere
with basal NF-κB signaling, only with in-
flammatory signaling through the IKK
complex (13,23). Also important for re-
ducing undesired side effects is a ther-
apy’s functional specificity. NBD has
been shown to be specific for inhibiting
NF-κB signaling, exhibiting no inhibitory
effects toward JNK or p38 MAPK path-
ways (13). The safety profile for NBD is
favorable as well. In vivo, systemic deliv-
ery of NBD is not associated with any de-
scribed toxicity in mice or rats and inhibi-
tion of NF-κB has been demonstrated to
ameliorate an ever-growing list of
 inflammatory disease conditions (33,34,
37,39–41). Furthermore, in a mouse
model of arthritis, systemic administra-
tion of NBD for only 5 days was suffi-
cient to maintain clinical improvement
for nearly 3 weeks (41), demonstrating
that the therapeutic effect of the NBD
peptide may outlast the pharmacokinetic
properties of this peptide.
In this study, we demonstrate the fea-
sibility of pursuing the NBD peptide as a
therapeutic for alleviating DMD patho-
physiology. The development of a GLP-
approved, water-soluble peptide that
ameliorates muscle functional deficits,
inflammation and necrosis while pro-
moting muscle regeneration in mdx mice
provides preclinical evidence for the effi-
cacy and safety of the NBD peptide.
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